Targeting IL-5 in severe asthma: A DREAM come true?

The Lancet

Volumn 380, Issue 9842, 2012, Pages 626-627

  Hashimoto, Simone ^a   Bel, Elisabeth H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 5; MEPOLIZUMAB; NITRIC OXIDE; PLACEBO;

AIRFLOW; ASTHMA; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIC ASTHMA; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); NOSE POLYP; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; RISK FACTOR; SMOKING; TREATMENT RESPONSE;

EID: 84865151725     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61132-5     Document Type: Note

References (14)

1. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-19.
2. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-24.
3. Moore WC, Meyers DA, Wenzel SE, et al. Identifi cation of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-23.
4. Pavord ID, Haldar P, Bradding P, Wardlaw AJ. Mepolizumab in refractory eosinophilic asthma. Thorax 2010; 65: 370.
5. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-21.
6. Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airfl ow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164: 744-48.
7. Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104: 394-403.
8. van Veen IH, Ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in diffi cult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 2009; 124: 615-17.
9. Wenzel SE. Eosinophils in asthma-closing the loop or opening the door? N Engl J Med 2009; 360: 1026-28.
10. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
11. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-93.
12. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-59.
13. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identifi cation of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-71.
14. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAB, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128: 989-95.